Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes

Osman, Abdimajid; Fälker, Knut

doi:10.3109/09537104.2011.560305

Cited by 100 publications

(93 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this result is in alignment with a study done in 2009 by Landry et al (23) which showed that mRNA translation in blood platelets is regulated by miRNA and that different miRNAs was described to affect biosynthesis of platelets like miR-15 a, miR-339-3 p and miR-365 (24) . There were no previous studies that specifically correlated miR-9 to platelets or explained the exact mechanism by which miR-9 affect megakaryocytopoiesis.…”

Section: Discussionsupporting

confidence: 78%

Expression of micro RNA-9 in Patients with Acute Myeloid Leukemia and its Impact on Treatment Strategy

Youssef

Ismail²,

Attia³

et al. 2018

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is a malignant disorder of hematopoietic tissue. It is one of the most common malignancies in adults. It is characterized by its heterogeneous and complex nature that includes chromosomal, genetic and epigenetic abnormalities. MicroRNAs have been described to be one of the epigenetic regulators in AML. Objective: The present study focused on measuring expression levels of miR-9 in de novo AML patients. 30 bone marrow samples were collected from patients attending at Hematology and Oncology Unit of Aldemerdash Hospitals.MiR-9 expression levels were measured using real time PCR. These expression levels were compared to 30 adult healthy volunteers. Patients and Methods: The present study was carried out in medical oncology and Clinical Pathology Departments of Ain Shams University and National Research Centre, Egypt during the period between September 2017 and April 2018. Results: Statistical analysis of the results showed that miR-9 was significantly down regulated in AML patients in comparison to controls. It is also significantly correlated to platelet count. Regarding diagnostic performance, this study showed that miR-9 has weak diagnostic performance but regarding screening function, it has perfect sensitivity but weak specificity so it can be used as an excluding test. Conclusion: This study showed reduction of miR-9 in bone marrow of AML patients and opened the horizon for future studies on diagnostic and screening performance of miR-9 to be performed on larger scale and different ethnic groups.

show abstract

Section: Discussionsupporting

confidence: 78%

Expression of micro RNA-9 in Patients with Acute Myeloid Leukemia and its Impact on Treatment Strategy

Youssef

Ismail²,

Attia³

et al. 2018

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…A few studies mapping the full platelet miRNA repertoire have been conducted since then, 24,25 but to our knowledge, no one has studied the platelet miRNA transcriptome in patients with myocardial infarction. In an effort to address this question we conducted RNA-seq of highly purified platelet preparations from patients with STEMI and from healthy individuals.…”

Section: Discussionmentioning

confidence: 99%

Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression

Gidlöf

Brug

Öhman

et al. 2013

Blood

235

234

View full text Add to dashboard Cite

• Patients with myocardial infarction have altered platelet miRNA profiles.• Activated platelets release miRNAs that can be taken up by endothelial cells and regulate ICAM-1 gene expression.Platelets play a crucial role in the pathogenesis of myocardial infarction (MI) by adhering to the site of a ruptured atherosclerotic plaque. The aim of this study was to screen for differences in the micro RNA (miRNA) content of platelets from patients with myocardial infarction and control patients, to investigate a possible release of miRNAs from activated platelets and to elucidate whether platelet-derived miRNAs could act as paracrine regulators of endothelial cell gene expression. Using RNA-seq, we found 9 differentially expressed miRNAs in patients compared with healthy controls, of which 8 were decreased in patients. Of these, miR-22, -185, -320b, and -423-5p increased in the supernatant of platelets after aggregation and were depleted in thrombi aspirated from MI patients, indicating the release of certain miRNAs from activated platelets. To confirm that endothelial cells could take up the released platelet miRNAs, transfer of both fluorescently labeled miRNA and exogenous celmiR-39 from activated platelets to endothelial cells was shown. Finally, a possible paracrine role of released platelet miR-320b on endothelial cell intercellular adhesion molecule-1 expression was shown. Thus, platelets from patients with MI exhibit loss of specific miRNAs, and activated platelets shed miRNAs that can regulate endothelial cell gene expression.

show abstract

“…Recently published data demonstrates an important role of microRNA in human megakaryocytopoesis [34][35][36][37][38][39]. Despite their lack of nuclear DNA, platelets contain significant amounts of microRNA that have important functions in post-transcriptional gene regulation [37,38,40].…”

Section: Methods For the Assessment Of Platelets Involvement In The Fmentioning

confidence: 99%

Role of Platelets in Thromboembolism in Patients with Atrial Fibrillation

2015

View full text Add to dashboard Cite

of patients with AF is diversified. The rate of thromboembolic complications, predisposing factors and destination of embolism are different in valvular atrial fibrillation (VAF) and non-valvular atrial fibrillation (NVAF). Patients with VAF have a higher risk of thromboembolism and a higher prevalence of thrombus location within the body of the left atrium compared to NVAF. VAF is also associated with higher propensity for non-cerebral thromboemboli than in NVAF [5]. There are many as yet unanswered questions surrounding the increased thrombotic tendency in AF. One of the crucial questions is what determines the fact that a thrombus in the left atrium remains in situ in some patients, while in others it breaks off and leads to embolic complications.As in other disorders, the risk of thromboembolic complications in AF is related to the triad of factors proposed by Rudolf Virchow: abnormalities in blood flow, endocardial/vessels wall damage and alterations in blood composition.Symptomatic thromboembolic complications are diagnosed annually on average in 5% of patients with atrial fibrillation (AF); however, the incidence rate of these complications varies over a broad range, from 0.5 to over 20% per year depending on coexisting risk factors [1]. Thromboembolic complications secondary to AF are a major cause of mortality and disability. The most common complication of AF is stroke, accounting for between 80% and over 90% of all embolic events [2]. Embolization of peripheral arteries with thrombotic material originating in the left atrium occurs much less commonly; however, in the group of patients having surgery due to peripheral embolism, 60-95% are diagnosed with AF [3].Thrombus formation in the left atrium can be triggered by a range of factors, both inherited and acquired. It is necessary to take into account factors directly associated with the cardiac rhythm disorder and concomitant diseases [4] AbstractThromboembolic complications of atrial fibrillation (AF) are a major cause of morbidity and mortality but the mechanism of its process remain poorly understood. There are many as yet unanswered questions surrounding the increased thrombotic tendency in AF. One of the crucial questions is what determines the fact that a thrombus remains in the left atrium in situ in some patients, while in others it breaks off and leads to embolic complications. Recent studies indicated an important role of platelets in the left atrial's thrombus formation and suggest that the embolic potential of left atrial thromboses depends on the involvement of platelets in the process of fibrin stabilization rather than aggregation. New methods for investigating platelets function, such as the analysis of transcription activity of RNA coming from platelets contained in thrombi formed in AF, creates an opportunity for studying populations of platelets that are directly involved in homeostatic clot formation. In this paper we present current opinions on the participation of platelets in the pathogenesis of thromboembolism in patients with...

show abstract

Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes

Cited by 100 publications

References 33 publications

Expression of micro RNA-9 in Patients with Acute Myeloid Leukemia and its Impact on Treatment Strategy

Expression of micro RNA-9 in Patients with Acute Myeloid Leukemia and its Impact on Treatment Strategy

Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression

Role of Platelets in Thromboembolism in Patients with Atrial Fibrillation

Contact Info

Product

Resources

About